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Abstract
In this study, we used deletions at 22q13, which represent a substantial source of human pathology (Phelan/McDermid
syndrome), as a model for investigating the molecular mechanisms of terminal deletions that are currently poorly
understood. We characterized at the molecular level the genomic rearrangement in 44 unrelated patients with 22q13
monosomy resulting from simple terminal deletions (72%), ring chromosomes (14%), and unbalanced translocations (7%).
We also discovered interstitial deletions between 17–74 kb in 9% of the patients. Haploinsufficiency of the SHANK3 gene,
confirmed in all rearrangements, is very likely the cause of the major neurological features associated with PMS. SHANK3
mutations can also result in language and/or social interaction disabilities. We determined the breakpoint junctions in 29
cases, providing a realistic snapshot of the variety of mechanisms driving non-recurrent deletion and repair at chromosome
ends. De novo telomere synthesis and telomere capture are used to repair terminal deletions; non-homologous end-joining
or microhomology-mediated break-induced replication is probably involved in ring 22 formation and translocations; non-
homologous end-joining and fork stalling and template switching prevail in cases with interstitial 22q13.3. For the first time,
we also demonstrated that distinct stabilizing events of the same terminal deletion can occur in different early embryonic
cells, proving that terminal deletions can be repaired by multistep healing events and supporting the recent hypothesis that
rare pathogenic germline rearrangements may have mitotic origin. Finally, the progressive clinical deterioration observed
throughout the longitudinal medical history of three subjects over forty years supports the hypothesis of a role for SHANK3
haploinsufficiency in neurological deterioration, in addition to its involvement in the neurobehavioral phenotype of PMS.
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Introduction
Deletions involving the distal portion of chromosomes are
among the most commonly observed rearrangements detected by
cytogenetics [1] and result in several well-known genetic
syndromes such as 1p36 monosomy (MIM: 607872), Cri-du-chat
(5p-, MIM: 123450), Miller-Dieker (17p-, MIM: 247200),
monosomy 18q (18q-, MIM: 6011808) monosomy 9p (MIM:
158171), Wolf-Hirschhorn (4p-, MIM: #194190), 9q34.3 micro-
deletion (MIM: 610253), monosomy 2q37 (MIM: 600430) and
Phelan-McDermid (PMS, MIM: 606232) syndromes. Over the
past 15 years, technological advances in the molecular cytogenetic
diagnosis of mental retardation, such as subtelomere screening and
high-resolution genome analysis, have strongly enhanced the
detection rate of an increasing number of chromosome rearrange-
ments involving subtelomeric regions associated with mental
retardation.
Telomere loss caused by double-strand breaks (DSBs) can
generate, if not properly repaired, chromosome instability, cell
senescence, and/or apoptotic cell death. Terminal deletions can
be repaired and stabilized through the synthesis of a new telomere
(telomere healing), demonstrated through sequence analysis of
terminal deletions that showed de novo telomeric repeats attached
to the remaining chromosomal sequences [2–4]; by telomerase-
independent recombination-based mechanisms [5,6]; by obtaining
a telomeric sequence from another chromosome (telomere
capture) resulting in derivative chromosomes [7,8]; finally, by
chromosomal circularization, leading to the formation of a ring
chromosome [9,10]. However, in spite of their relatively frequent
occurrence, the molecular bases for generating and stabilizing
terminal chromosome deletions in humans are still poorly
understood, since the breakpoints have been analyzed at the
base-pair level in only few studies [11,12]. Questions remain about
the timing of breakpoint repair, the relative importance of the
above-mentioned mechanisms in terminal deletions affecting
specific chromosomes, the role of repetitive elements, long
terminal repeats and other DNA elements in chromosome
breakage and stabilization.
In this study, we used deletions of 22q13, which represent a
substantial source of human pathology [13,14], as a model for
investigating the molecular mechanisms of terminal deletions.
We characterized at the molecular level 40 new and 4
previously published subjects with 22q13 chromosome rearrange-
ments [15,16] aiming to identify the molecular mechanisms
involved in stabilizing the deletions in patients with monosomy
22q13 and, more generally, to obtain new insight in the
mechanisms underlying terminal deletions. Genotype-phenotype
relationship, including the detailed clinical history of three adult
patients that may help to define the lifelong outcome of PMS, is
also discussed.
Results
Clinical profile of patients with 22q13 microdeletion
syndrome
Patients included 26 females and 18 males, with ages ranging
from birth to 47 years. Six patients (P25–29, P33) had a ring
chromosome 22, five (P37–38, P42–44) had interstitial 22q13.3
deletions, three (P11, P15, P16) carried derivative chromosomes,
while the remaining patients had terminal deletions (Table 1).
We excluded from the clinical analysis patients with a derivative
chromosome 22 (P11, P15, P16) and subject P28 with a complex
ring 22 rearrangement, since the additional duplicated regions
could complicate the assessment.
The features observed in the 40 cases in our series were
compared to the characteristic features of the 22q13 deletion
syndrome [17] (Table S1).
Clinical medical history of adult patients. Since to date
old patients with 22q13.3 deletion syndrome have not been
described and no longitudinal data are available to determine their
life expectancy, we report the medical and clinical history of three
adult patients over forty years (P10, P30 and P33) (Text S1 for
additional medical details).
Subject P10:
The patient is a woman referred to a geneticist at the age of 40
years in the context of a diagnostic evaluation of people living in an
institution for mentally disabled people. She presented absence of
language and severe mental retardation. Facial dysmorphisms were
also evident (Figure S1F–S1J). Neurological evaluation showed
spastic paraparesis. At age 39, she suffered from frequent epileptic
seizures, in spite of antiepileptic drugs. At age 43, she experienced
very fast motor and cognitive decline; as a consequence, she was not
able to stand, walk or even make eye contact anymore; her spastic
tetraparesis markedly increased. Right renal agenesis was diagnosed
during a control abdominal ultrasonography. She died at 47 years
for renal failure while in a vegetative state.
Subject P30:
The patient is a woman referred for clinical genetics evaluation
at the age of 40 years because of severe cognitive impairment and
mild craniofacial dysmorphisms. She suffered from epilepsy,
cortical tremor (starting at the age of 39 years) and poor speech.
Minor facial dysmorphic features were observed (Figure S1A–
S1E).
Subject P33:
The patient is a male first referred to a geneticist at the age of 41
years in the context of familial genetic counseling. The
dysmorphological examination revealed evident aspecific dysmor-
phisms (Figure S1K–S1N). He presented with total absence of
language, severe mental retardation, delayed motor development
and microcephaly. At the age of 34 years, he developed type 2
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had three spontaneous pneumothorax episodes at the upper lobe
of his left lung.
Patients with cryptic interstitial 22q13.3 deletion
disrupting the SHANK3 gene. The clinical features of five
cases with microdeletions involving only SHANK3 (P37, P44) or
SHANK3 and ACR (P38, P42–43) are summarized in Table 2; their
detailed medical history is described in Text S1.
Parental origin of the deletions
The parental origin of the de novo 22q13 rearrangements was
elucidated in 30 families (Table 3).
The majority of terminal (17/23) and interstitial (2/2) deletions
for which parental origin was available had paternal origin. Three
of five ring 22 cases (60%) were also of paternal origin, while two
were maternal.
Molecular characterization of 22q13 deletions
We collected 40 new unrelated patients with 22q13 deletions
and re-analyzed four previously published cases (Table 1).
Nine subjects (P2, P8, P10, P14, P17, P20, P36, P40, P41)
showed a 22q13 deletion on high- resolution G- banding
karyotype (550 bands); in three of them, previous low resolution
banding karyotype had missed the rearrangement. Six cases
showed a ring 22 at karyotype analysis. One of them (P29) was a
mosaic. In one subject (P31), the presence of a terminal 22q13.3
microdeletion was first suspected in a routine subtelomere
screening by multiplex ligation-dependent probe amplification
(MLPA, kit P036, MRC Holland) that showed a possible deletion
at the RABL2B locus, and subsequently diagnosed by aCGH
analysis (244k, Agilent). Subtelomeric FISH screening with cosmid
clones covering the distal 22q-140 kb [18] (data not shown) further
confirmed the terminal 22q13.3 microdeletion with breakpoint
between exons 8–9 of the SHANK3 gene. The remaining twenty-
four patients had normal karyotype results and were ascertained
either through subtelomere-FISH or array-CGH analysis.
Whole-genome array-CGH using several available platforms
(44k, 105k, 244k) was performed on all patients diagnosed through
classical cytogenetic methods, except for subject P35, in order to
determine the genomic size of the deletion and exclude any
concurrent microdeletion/microduplication elsewhere in the
genome.
This approach allowed the identification of 22q13 deletions,
varying in size between 0.14 and 9.0 Mb, in 39 subjects (Figure 1).
The breakpoints were scattered along the 22q13 region and no
breakpoint grouping was observed. We precisely delineated the
boundaries of each deletion by commercial high-resolution (244k,
Agilent) or customized aCGH analysis. Further improvements in
resolution, obtained with subject-specific qPCR amplification
experiments, allowed the design of oligonucleotide primers to
specifically amplify the junction fragments.
Terminal deletions
We attempted to clone the deletion breakpoints of all 33
patients with apparently terminal 22q13 deletions by postulating
healing of the truncated 22q sequences through the addition of a
new telomere sequence at the breakpoint. Forward primers were
designed proximally to each breakpoint and used for nested PCR,
together with telomere-specific primers. Using this strategy, we
isolated twenty-two breakpoints from 20 cases with terminal
deletions (P1, P3–P8, P12–P14, P20, P21, P30–P32, P34, P36)
(Figure S2). Nineteen breakpoints from 17 subjects contain 3–48
copies of the GGTTAG hexamer. Alignment of the chromosome-
specific sequences flanking the telomeric repeats with the human
genome reference sequence revealed the immediate proximity of
the repeats to the chromosome-specific sequences in 16 break-
points. Three breakpoints (P20 BP3, P8, P7) contain 2, 14, and 20
additional bases not present in the reference sequence, respective-
ly. Two subjects (P31, P32) carry recurrent 22q terminal deletions
[18]. The junction fragment in subject P8 contains a perfect 7-bp
inverted palindrome. Thirteen of the 19 breakpoints fall inside
repetitive sequences (SINE, LINE, DNA-type, simple repeats)
(Figure S2). One breakpoint junction (P2) contains a (GGTGAG)n
repeat, fortuitously amplified because of its homology with the Tel-
ACP primer, instead of the expected (GGTTAG)n. In a second
junction (P39), the telomere sequence is preceded by (GGTCAG)6.
A third breakpoint (P40) is joined to the terminal 450 bp of a Xp/
Yp chromosome arm.
Interestingly, high-resolution aCGH analysis allowed the
identification of a patient (P20) carrying a mosaic of at least three
lines with 22q13.2 terminal deletions, each with a different
breakpoint (Figure 2A). All breakpoints were located in a ,400 kb
interval. FISH analysis with clone RP11-141N8 (AQ388763 at
22q13.2), positioned between BP1 and BP2 (Figure 2A, 2B)
confirmed the presence of a mosaic deletion in 30% of the
metaphases analyzed (Figure 2B). We cloned all three identified
breakpoints: the more proximal is located in intron 11 of the
EFCAB6 gene; the intermediate falls in a MER5B repeat; the more
distal in a Tigger5 repeat (Figure 2C). High-resolution aCGH
profiling suggested the presence of at least two mosaic breakpoints
in a second patient (P12) (Figure S3A, S3B), but we were only able
to clone one of them (Figure S3C).
Interstitial deletions
Our series also includes five patients with interstitial 22q13.3
deletions disrupting the SHANK3 gene (P37, P38, P42–44) (Table 2,
Figure 3A, 3B). The region distal to the deletions in P38 and P42
lies in a paralogous sequence containing the RABL2B gene, with
almost complete identity with the chromosome 2 region
containing RABL2A, and only one 180k/244k (Agilent) aCGH
Author Summary
Terminal chromosome deletions are among the most
commonly observed rearrangements detected by cytoge-
netics and may result in several well-known genetic
syndromes. We used 22q13 deletions to study how these
types of chromosome abnormalities arise. Children with
Phelan/McDermid syndrome, caused by deletion of the
terminal portion of chromosome 22, experience develop-
mental delay, absent or severely delayed speech, and
frequent behavioral problems. Lack of one copy of
SHANK3, a key gene for the correct development and
organization of brain synapses, is very likely the basis of
the syndrome’s major neurological features. Deletion of
additional genes probably causes more complex pheno-
types in subjects with larger deletions. We also studied
patients who only lack a portion of SHANK3 and
demonstrated that small, hard-to-detect deletions of this
gene may cause substantial clinical problems. Until now,
the 22q distal deletion had been only diagnosed in very
young people. We studied a large group of patients of
different ages and discovered that all adult patients face
progressive cognitive decline. Our study demonstrates
that deletion of the terminal portion of chromosome 22, a
prototype for terminal deletions in human chromosomes,
can occur in several ways. Mosaic deletions of different size
can also form in early embryogenesis.
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Patient Gender
Ascertainment
method Karyotype Rearrangement
Del22q13
size
Associated genome
imbalance, size
Repair
mechanism
Parental
origin
P1 M Tel-FISH Del(22)(q13.3)dn Terminal deletion 0.9 Mb Telomere healing Pat
P2 F K Del(22)(q13.31)dn Terminal deletion 5.38 Mb Telomere capture Pat
P3 F Tel-FISH Del(22)(q13.32)dn Terminal deletion 2.5 Mb Telomere healing Mat
P4 M Tel-FISH Del(22)(q13.32)dn Terminal deletion 1.64 Mb Telomere healing U
P5 F K Del(22)(q13.31)dn Terminal deletion 6.5 Mb Telomere healing Pat
P6 M Tel-FISH Del(22)(q13.32)dn Terminal deletion 2.65 Mb Telomere healing Mat
P7 F Tel-FISH Del(22)(q13.31)dn Terminal deletion 3.5 Mb Telomere healing Mat
P8 M K Del(22)q(13.32)dn Terminal deletion 8.1 Mb Telomere healing Pat
P9 M Tel-FISH Del(22)(q13.31)dn Terminal deletion 0.8 Mb Pat
P10 F K Del(22)(q13.2)dn Terminal deletion 8.1 Mb U
P12 F aCGH Del(22)(q13.31)dn Terminal deletion 4.98 Mb Telomere healing Pat
P13 F aCGH Del(22)(q13.3)dn Terminal deletion 1.08 Mb Telomere healing U
P14 F K Del(22)q(13.31)dn Terminal deletion 5.8 Mb Telomere healing U
P17 M K Del(22)(q13.2)dn Terminal deletion 7.6 Mb Pat
P18 F Tel-FISH Del(22)(q13.31)dn Terminal deletion 4.7 Mb U
P19 M Tel-FISH Del(22)(q13)dn Terminal deletion 3.7 Mb U
P20 F K Del(22)q(13.2q13.3)dn Terminal deletion 7.2 Mb Telomere healing Pat
P21 F Tel-FISH Del(22)(q13.31)dn Terminal deletion 4.7 Mb Telomere healing Mat
P22 F Tel-FISH Del(22)(q13.32)dn Terminal deletion 1.9 Mb Mat
P23 M aCGH Del(22)(q13.31)dn Terminal deletion 3.4 Mb Pat
P24 F aCGH Del(22)(q13.32)dn Terminal deletion 1.8 Mb Pat
P30 F aCGH Del(22)(q13.31) Terminal deletion 3.4 Mb Telomere healing Pat
P31 M Tel-MLPA, aCGH Del(22)(q13.33)dn Terminal deletion 122,392 bp Telomere healing Pat
P32 F aCGH Del(22)(q13.33)dn Terminal deletion 122,388 bp Telomere healing Pat
P34 M Tel-FISH Del(22)(q13.31)dn Terminal deletion 4.4 Mb Telomere healing Pat
P35 M Tel-FISH Del(22)(q13.31)dn Terminal deletion ,4M b U
P36
b F K Del(22)(q13.2)dn
mosaic 75%
Terminal deletion 9.0 Mb Telomere healing Pat
P39 M aCGH Del(22)(q13.3q13.3) Terminal deletion 122,498 bp Telomere capture Pat
P40 F K Del(22)(q13.2q13.3) Terminal deletion 7.4 Mb Telomere capture Mat
P41 F K Del(22)(q13.31q13.3) Terminal deletion 5.8 Mb Pat
P37 F aCGH Del(22)(q13.3q13.3) Interstitial deletion 73,833 bp NHEJ Pat
P38 F aCGH Del(22)(q13.3q13.3) Interstitial deletion 44,174 bp NHEJ Pat
P42 M aCGH Del(22)(q13.3q13.3) Interstitial deletion 17,626 bp FoSTeS U
P43 F aCGH Del(22)(q13.3q13.3) Interstitial deletion 26,914 bp NHEJ U
P44 M aCGH Del(22)(q13.3q13.3) Interstitial deletion 38,948 bp NHEJ U
P25 F K Del(22)(q13.32)dn Ring 22 2.16 Mb Pat
P26 F K Del(22)(q13.33)dn Ring 22 1.2 Mb NHEJ U
P27 M K Del(22)(q13.31)dn Ring 22 5.2 Mb Mat
P28 F K Del(22)q(13.33)dn Ring 22 0.45 Mb Dup(22)(q11–q13.23), 18 Mb
Dup(22)(q12.3–q13.2), 4.2 Mb
Mat
P29 M K Del(22)(q13.31)dn
mosaic 30%
Ring 22 3.2 Mb Pat
P33 M K Del(22)(q13.32)dn Ring 22 2.04 Mb Pat
P15
a F K Del(22)(q31.31)mat Derivative chromosome 4.3 Mb Dup(12q24.33qter), 0.503 Mb NHEJ Mat
P16
a M K Del(22)(q31.31)mat Derivative chromosome 4.3 Mb Dup(12q24.33qter), 0.503 Mb NHEJ Mat
P11
a F K Del(22)(q13.31)pat Derivative chromosome 5 Mb Dup(12q24.32qter),
5.7 Mb
NHEJ Pat
K: karyotype; Tel-FISH: Subtelomeric Fish analysis (Tel Vysion Vysis or Tel kit Cytocell);Tel-MLPA: MLPA analysis of the 22q subtelomeric region; aCGH: array-CGH; F:
female; M: male; Mat: maternal, Pat: paternal; Mb: megabases; bp: base pairs. The total size is calculated between breakpoints or between the breakpoint and the end of
chromosome 22 assembly (UCSC hg18).
aReference [15];
bReference [16].
doi:10.1371/journal.pgen.1002173.t001
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spanning the terminal 100 kb of distal 22q (data not shown) and
qPCR experiments confirmed the findings. Specific amplification
of the junctions by long-range PCR followed by sequencing
analysis precisely defined each rearrangement’s structure
(Figure 3C, Figure S2).
The 74 kb interstitial deletion in P37 encompasses exons 1–
17 of SHANK3; the 44 kb deletion in P38 covers exons 19–23 of
SHANK3 and the whole ACR gene; the 18 kb deletion in P42
includes exon 23 of SHANK3 and exons 1–3 of ACR;t h e2 7k b
deletion in P43 includes exons 20–23 of SHANK3 and exons 1–3
of ACR; the 34 kb deletion in P44 overlaps exons 1–9 of
SHANK3 (Figure 3B). We found no homology between any
proximal and distal breakpoint region. Repeated sequences
(LTR and LINE) are present in three breakpoints; ten
additional nucleotides were inserted at the junction of P37
(Figure S2). In P42, the breakpoint junction contains 23–29 bps
identical to the reverse complement of a sequence in the middle
of the deleted region; this sequence shows 4 and 2 bp
microhomologies with the proximal and distal breakpoints,
respectively (Figure 3C).
Ring 22 chromosomes
Six subjects (P25–P29, P33) carry a 22q13 terminal deletion
associated to ring 22 chromosome; one of them (P29) shows a
mosaic deletion in 30% of the cells (not shown). We also identified
a complex ring 22 rearrangement consisting of a 240 kb terminal
22q deletion, concurrent with two additional, non-contiguous,
,18 Mb and ,4.2 Mb 22q duplications at 22q11–q12.3 and
22q12.3–q13.2, respectively, in subject P28 (Figure S4).
The only breakpoint we were able to identify in a patient with
ring 22 (P26) (Figure S5A) was cloned using inverse PCR and
shows a junction between an Alu sequence on 22q and a repeated
sequence with homology to pericentromeric and subtelomeric
regions on several chromosomes (Figure S5B). There is no
homology between the two breakpoints. In this case, as well as
in cases P27 and P29, we verified the absence of interstitial pan-
telomeric sequences with a PNA probe (Figure S5C). Unfortu-
nately, FISH analysis could not be performed on the remaining
three cases (P25, P28, P33) due to the lack of archival material.
Unbalanced translocations
Three patients (P11 and brother/sister pair P15–16) (Cases 1, 2,
and 3, respectively, in [15]) carry a derivative chromosome 22
inherited from a parent carrier of a balanced translocation.
In case P11, aCGH analysis identified the loss of a 5 Mb segment
of distal 22q13.31–q13.3 and the gain of a 5.7 Mb region of
chromosome 12q24.32–q24.33 (Figure S6A); the proband’s father
carries a balanced 12q;22q translocation. We amplified the junction
between 12q24.32 and 22q13.31 by long-range PCR using a
forward primer (22F) from the der(22) undeleted flanking region
and a reverse primer (12R) corresponding to the 12q duplicated
region. The same fragment was amplified from the carrier father
but not from the mother or other control DNAs (not shown).
Sequencing of the junction fragments revealed that the two
breakpoints share only a 4 bp microhomology (Figure S6B).
Table 2. Clinical characteristic of PMS in subjects with interstitial 22q13 microdeletions.
Clinical characteristic P37 P38 P42 P43 P44 Delahaye et al [41] TOT
Growth
Normal/accelerated + short stature +++ 4/6
Neurodevelopment
Hypotonia +
a 2 2222 1/6
Developmental delay ++ ++++ 6/6
Delayed/absent language ++ ++++ 6/6
Autism 2 + 2 + 22 2/6
Facial dysmorphisms +
b + 22+
c + 3/6
Extremities
Large and flashy hands 22 222+ 1/6
2
nd–3
rd toe syndactyly 22 222+ 1/6
aabdominal hypotonia;
Facial dysmorphisms overlapping those observed in PMS:
bsubject P37: wide nasal bridge, puffy cheeks, pointed chin, bulbous nose;
csubject P44: flat midface, long eyelashes, wide nasal bridge, puffy cheeks, bulbous nose, large/dysplastic ears.
doi:10.1371/journal.pgen.1002173.t002
Table 3. Parental origin of the de novo 22q13 deletions.
Chr. 22 anomaly Informative cases (N) Paternal origin (%) Maternal origin (%)
del(22) 25 19 (76%) 6 (24%)
ring 22 5 3 (60%) 2 (40%)
Total 30 22 (73%) 8 (27%)
doi:10.1371/journal.pgen.1002173.t003
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from their mother who carries a balanced 12q;22q translocation.
The two sibs carry a 4.3 Mb 22q13 deletion and a 0.5 Mb
12q24.33–q24.33 duplication (Figure S6C). In these patients, the
rearrangement is between an Alu repeat on chromosome 22q and a
(TGAG)n simple repeat on chromosome 12q. The two breakpoints
share only a 5-bp microhomology (Figure S6D).
Discussion
The constitutional 22q13 deletion is a fairly recently described
genomic disorder that results in global developmental delay,
delayed/absent speech, hypotonia and minor dysmorphic features.
In spite of the fact that to date more than 100 cases (excluding ring
22s) have been detected by different molecular methods, when and
Figure 1. Schematic representation of the 22q13 rearrangements. An ideogram of chromosome 22 is shown at the top with genomic
coordinates of the boxed terminal region of interest shown at 1 Mb intervals. The location of the SHANK3 gene is marked in red. Each patient is
represented by a horizontal line corresponding to the size of his deletion as determined by aCGH analysis. Each patient’s code number is shown on
the right side of the lines; asterisks (*) indicate previously published cases. Double asterisks (**) indicate mosaic deletions. The lines’ colors correspond
to 22q13 rearrangement categories: simple deletions are depicted in black, derivative chromosomes 22 in green, rings 22 in pink, and interstitial
deletions in brown. Forty-four patients are represented; the breakpoint interval (represented in grey) in subject P35 was narrowed down to ,400 kb
by FISH analysis with BAC clones RP11-194L8 (chr22:44,951,438–45,122,714, still present) and RP11-266G21 (chr22:45,543,178–45,711,912, deleted).
doi:10.1371/journal.pgen.1002173.g001
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characterized from the clinical and molecular points of view 44
subjects with PMS resulting from simple 22q13 deletions (30
subjects, 72%), ring chromosomes (six subjects, 14%), unbalanced
translocations (three subjects, 7%) and interstitial deletions (five
subjects, 9%); all rearrangements result in haploinsufficiency of the
SHANK3 gene (Table 1). We have also determined the breakpoint
junction sequences of twenty subjects with terminal deletions, five
with interstitial deletions, one with ring 22 and three with
unbalanced translocations.
Clinical profile and genotype/phenotype comparison
Although in our cases age at diagnosis ranged from birth to 41
years, no specific clinical phenotype diagnostic for 22q13 deletion
could be identified at any age (Table S1), as already noted by
Phelan et al. [13]. Thus, successful diagnosis of this syndrome
depends almost exclusively on the use of molecular diagnostic
tools, mainly subtelomeric FISH and high-resolution genome-wide
array-CGH. The latter is also suitable to identify cryptic interstitial
deletions involving only the SHANK3 gene, that are associated with
an even less specific phenotype, as observed in our five patients
(P37, P38, P42–P44). Their phenotype consisted mainly of
developmental and language delay. PMS-suggestive facial dys-
morphisms and hypotonia (limited to abdominal muscles) were
observed only in one patient (P37), while no other physical
abnormalities were noted in any of the patients. (Table 2). In
patient P43, a defect in the abdominal wall with gut protrusion
was detected by ultrasound during pregnancy and surgically
corrected immediately after birth.
Owing to its emerging role in neuropsychiatric disorders and to
the phenotypic overlap between autism and PMS, SHANK3 has
become a target for mutation screening in patients with autistic
Figure 2. Molecular characterization of the 22q13.2 terminal deletion in subject P20. A, Magnified view of the aligned breakpoint
boundaries detected by array-CGH analysis using an oligonucleotide-based custom 22q13 microarray (top) and a 180k Agilent kit (bottom); the
deleted regions are shaded in blue. Arrowheads delimit two mosaic-deleted regions: the BP1–BP2 deletion region (from 42406240 to 42603381 bp)
has an average log ratio of 20.3; the BP2–BP3 deletion region (from 42603381 to 42726895 bp) has an average log ratio of 20.5; the deleted region
between BP3 and the telomere (from 42726895 to the end of chromosome 22) has an average log ratio of 20.8. The aligned UCSC map (hg18) is
depicted at the bottom. The red bar indicates the map position of the RP11-141N8 BAC clone we used to confirm by FISH the mosaicism of the BP1–
BP2 region. All genes (blue bars) mapping within the BP1–BP3 regions are shown. B, FISH analysis using the RP11-141N8 clone confirms a mosaic
deletion of the BP1–BP2 region revealing: (top) the presence of hybridization signals (green signal) on only one chromosome 22 (arrowhead) in 30%
of the metaphases analyzed; (bottom) the presence of hybridization signals (green signals) on both chromosome 22 homologues in the remaining
70% of the metaphases analyzed (bottom). C, Tel-ACP amplification and direct sequencing of the amplified fragments revealed the breakpoint
junctions at BP1, BP2 and BP3. A telomere repeat is present at all three breakpoints.
doi:10.1371/journal.pgen.1002173.g002
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discovered de novo mutations in such patients. Mutations in
SHANK3 have also been found in schizophrenia [22] and non-
syndromic intellectual disability [23]. The contribution of
additional genes to the 22q13 deletion phenotype has also been
debated. Very recently it has been proposed that deletion of the
IB2 gene (also named MAPK8IP2 or JP2), mapping 70 kb
proximal to SHANK3, may play a relevant role in PMS-associated
ASD [24].
Two of our patients with interstitial microdeletions disrupting
SHANK3 and ACR only (P38, P43) (Figure 3B) fulfill the clinical
criteria for a diagnosis of autism, while the others (P37, P42, P44),
do not (Table 2). Our findings emphasize the incomplete
penetrance of the ASD phenotype in PMS, while confirming a
role for SHANK3 in ASD. Additional deleted genes may contribute
more strongly to accessory features, such as dysmorphisms and
hypotonia, than to developmental and language delay.
Longitudinal clinical data on adult patients were collected in
three subjects aged 40, 41 and 47 years. The severe progressive
neurological deterioration reported in adult patients P10 (starting
when she was 39 years old) and P30 (aged 40 years) was also
described by Anderlid in a 30-year-old patient [25]. The minimal
overlapping 22q13 region deleted in these three cases contains
only SHANK3, RABL2B and ACR. In addition, subject P37
carrying an interstitial deletion involving only SHANK3 experi-
enced tremors and tics starting at age 23 (Text S1). Shank proteins,
that organize glutamate receptors at excitatory synapses, are
dramatically altered in Alzheimer disease [26]. In turn, disruption
of glutamate receptors at the postsynaptic platform had been
reported to contribute to the destruction of the postsynaptic
density underlying mental deterioration in Alzheimer disease [27].
According to our results, SHANK3 defects might indeed be
responsible for progressive neurodegeneration, in addition to
causing the neurobehavioral phenotype of the 22q13 syndrome.
Previous studies on a large cohort of patients with ring 22
demonstrated that there is considerable molecular and phenotypic
overlap between individuals with ring 22 and those with del 22q13
[28–29]. All six subjects reported here showed features commonly
found in 22q13.3 deletion syndrome, including accelerated growth
in two of them (P26, P27), whereas one (P25) had slightly delayed
growth.
Parental origin
Parental origin was determined in 30/44 cases. We observed a
larger proportion of 22q13 deletions of paternal (22/30, 73%),
compared to maternal (8/30, 27%) origin, in agreement with a
previous large study in which 69% of the deletions were of
paternal origin [14]. There was no deletion size bias. Interestingly,
we observed that both recurrent deletions (P31, P32), as all
previously reported cases [18,19,30], were of paternal origin.
Furthermore, the two interstitial deletions (P37, P38) we
characterized were also paternal. In other terminal deletion
cohorts, the majority of patients carry small 1p36 deletions on the
maternal chromosome, while larger deletions are predominantly
paternal [31]. In contrast, de novo simple small terminal 9q34.3
deletions are predominantly paternal, whereas larger terminal
deletions, interstitial deletions, complex rearrangements and
unbalanced translocations are frequently maternal in origin [12].
Telomere healing and capture in terminal deletions
Broken chromosome ends can be stabilized through at least
three mechanisms: de novo telomere addition mediated by
telomerase; telomere capture resulting in a derivative chromo-
some; stabilization by break-fusion-break (BFB) cycles, generating
Figure 3. 22q13.3 interstitial microdeletion detected by array-CGH analysis. A, aligned aCGH profile (P37–38, P43–44: 180k Agilent kit; P42:
244k Agilent kit) details of all interstitial deletions; the deleted regions are shaded. B, map of the distal 22q13.3 region; the deletions are represented
by black bars; the region overlapping the SHANK3 gene is shaded in light blue. All genes mapping in the region are shown. C, sequence alignment of
the breakpoint junctions of subject P42 showing the homology with three genomic regions. The proximal breakpoint sequence is shown in red, the
middle 24 bases in inverted orientation are blue, the distal breakpoint sequence in green; microhomologies between sequences at the breakpoints
are depicted in bold. D, cartoon showing the respective position and orientation of the breakpoint sequences in P42 as arrows, colored as in C.
doi:10.1371/journal.pgen.1002173.g003
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two mechanisms have been identified in this study. Almost 60% of
our patients carried apparently simple terminal deletions.
Nineteen of the twenty-two breakpoints we cloned, including all
three breakpoints in mosaic subject P20, show evidence of
telomere healing. Fourteen breakpoints contain 1–5 base micro-
homologies with the canonical GGTTAG sequence at the fusion
point of genomic and telomeric sequences (Figure S2), possibly
reflecting the template-driven mechanism that telomerase uses to
replicate chromosome ends [32,33]. The same mechanism applies
to terminal 4p deletions [34] where microhomology with telomere
repeats was found in all analyzed subjects. Human telomeres
contain large blocks of 100–300 kb TAR sequences, located just
proximally to the (TTAGGG)n tandem repeats, providing
significant sequence homology between non-homologous chromo-
some ends [35]. Two terminal deletions in our cohort (P2, P39)
were healed by telomere capture of TAR sequences (Figure S2).
One deletion (P40) was repaired by the capture of the distal
portion of Xp/Yp (Figure S2).
Failure to identify the nine remaining breakpoints may be due
to the presence of regions containing large repetitive sequences or
other complex sequences that would hinder amplification.
Alternatively, some of the deletions may lack a telomere repeat
at the breakpoint because the deletion may have been repaired by
alternative mechanisms.
The presence of short repetitive elements may play a role in
generating or stabilizing terminal deletions. In this study, we have
determined 42 breakpoint junctions within the 22q13 region.
Repetitive sequences, such as Alu, LINE, SINE, LTR and simple
repeats were often, but not always, present at or near the breakpoints
(Table S2). These repetitive elements are susceptible to DSBs due to
replication errors or to the formation of unusual secondary structures,
including cruciforms, hairpins, and tetraplexes [36]. On the other
hand, there isno hard proof that the breakpoints of terminal deletions
are the actual site of the original DSB, rather than the site where
telomerase was able to synthesize a new telomere sequence.
Analysis of case P20 revealed a mosaic of at least three cell lines
carrying different terminal 22q13 deletions. Their breakpoints
were located approximately 100 Kb from each other. This
mosaicism may be due to distinct stabilizing events, occurring in
different cells of the early embryo, of the same unstable terminal
deletion. Our results demonstrate that primary terminal deletion
breakpoints and repair sites are not necessarily coincident and can
actually be far apart. We had already shown, in an exceptional
case of mosaicism for maternal 22q13.2-qter deletion (45% of cells)
and 22q13.2-qter paternal segmental isodisomy (55% of cells) that
complex mosaicism can also arise from a postzygotic or early
embryonic recombination event [16]. These data suggest that
terminal deletions can be repaired by multistep healing events.
Cryptic mosaics may also render genotype-phenotype relationship
in deletions more complex than expected.
Deletion sizes in patients with monosomy 1p36 [31] and 9p21–
p24 [37] vary widely, up to 20 Mb, while 9q34.3 deletions [12] do
not exceed 3.5–4 Mb. The size of 22q13 deletions is highly
variable, ranging from 100 kb to 9 Mb [14]. No single common
breakpoint has been discovered in deletions of 1p36 [31] and
9q34.3 [12], both studied in great detail. In contrast, 9 cases with
terminal 140 kb deletion and a breakpoint occurring in a short
GC-rich simple repeat in intron 8 of the SHANK3 gene have been
reported [18,19,25,30,38,39]. In this study, we detected two new
unrelated cases (P31, P32) with the same recurrent terminal
deletion healed by de novo telomere addition. Computational
analysis [40] predicts that this repeat would be able to form a
secondary structure that may predispose to DNA double strand
breaks, stabilize the broken chromosome end, or recruit
telomerase more efficiently [36]. Subject P39 has a slightly larger
deletion repaired by the capture of a TAR sequence.
Interstitial deletions
Interstitial deletions affecting the 22q13 region have previously
been described in three cases, one disrupting the SHANK3 gene
[41] and two more proximal [42]; none of them has been finely
characterized at the molecular level. We characterized five
additional de novo interstitial deletions between 17 and 74 Kb in
size and sequenced their breakpoints: three of the deletions (P37,
P44) disrupt exclusively SHANK3, the others (P38, P42, P43) both
SHANK3 and ACR (Figure 3B).
The interstitial deletions in four patients (P37,38, P42, P44) are
compatible with NHEJ repair. P42 carries a more complex
rearrangement where 40–47 bp from the deleted region are
inserted in opposite orientation in the middle of the breakpoint
junction (Figure 3C). A DNA replication model named FoSTeS
[43], later generalized to the microhomology-mediated break-
replication (MMBIR) model [44], has been proposed to explain
complex rearrangements associated with several diseases. The
rearrangement in P42 can indeed be explained by the FoSTeS/
MMBIR mechanism (Figure 3D).
Apart from the cases described in this report, we have no
information on the percentage of defects in SHANK3 caused by
deletions/duplications involving only one or a few exons. The
small size of these rearrangements poses substantial problems for
their identification, at least with current commercial aCGH
platforms having necessarily limited coverage of the SHANK3
gene. Arrays designed for the detection of clinically relevant exonic
CNVs [45] may offer a solution.
Ring 22 chromosomes and unbalanced translocations
NHEJ is the most likely repair mechanism leading to ring 22
f o r m a t i o ni nc a s eP 2 6 .A st h i si st h eo n l yr i n g2 2b r e a k p o i n tw ew e r e
able to clone, we cannot be sure that the same mechanism will apply
to all cases with ring 22. Our inability to capture more breakpoints of
ring 22 deletions may stem from the occurrence of the 22p
breakpoints within highly repetitive sequences. Generation of
breakpoints at both arms of the same chromosome, followed by
circularization, has been usually assumed to be the basis of ring
chromosome formation. Alternatively, telomere healing through
circularization after the occurrence of a simple distal deletion, as it
seems the be the case for ring chromosomes with concurrent deletion
and duplication at one end [10], cannot be excluded. Thus, distal
deletions and ring chromosomes might share the same initial event.
We also demonstrated that the complex phenotype in one ring
22 patient (P28) can be explained by the presence of further
chromosome duplications at 22q11–12.3 and 22q12.3–13.2,
undetectable with conventional cytogenetic analysis, in addition
to the 22q13.3 deletion. The identification of the complex ring 22
rearrangement in this patient directly stems from the whole-
genome aCGH analysis required by our protocol in order to
exclude additional genomic aberrations.
All unbalanced translocations we analyzed (P11, P15, P16) were
inherited from a parent carrying a balanced translocation. The
microhomology found at all breakpoints points to NHEJ or
MMBIR as the most likely mechanisms for these rearrangements;
therefore they should be considered mechanistically different from
all previously discussed chromosome 22 rearrangements.
Conclusions
All adult patients with 22q13 deletion showed progressive
clinical deterioration, supporting the hypothesis of a role for
Mechanisms of Terminal 22q13 Deletion
PLoS Genetics | www.plosgenetics.org 9 July 2011 | Volume 7 | Issue 7 | e1002173SHANK3 haploinsufficiency in neurological deterioration. All
patients with interstitial deletions involving only SHANK3 showed
a neurological and behavioral phenotype, demonstrating once
again the specific role of the gene in this syndrome.
The study of breakpoints in subjects with 22q13 deletion
provides a realistic snapshot of the variety of mechanisms driving
non-recurrent deletion and repair at chromosome ends, including
de novo telomere synthesis, telomere capture and circularization.
Distinct stabilizing events of the same terminal deletion can also
occur in different early embryonic cells. These data are in
agreement with those demonstrating that mosaic structural
chromosome abnormalities are common in early IVF embryos
[46] and that chromosomally unbalanced zygotes are submitted,
during first mitotic divisions, to intense genomic reshuffling
eventually leading to different situations, all compatible with
survival [47]. As recently suggested, the burst of DNA replication
that accompanies the rapid cell division required to go from a
single post-zygotic cell to an embryo and then a fetus is a time in
the human life cycle when more new mutations may occur than
was previously appreciated. Depending on the timing, many such
events may be difficult, if not impossible, to identify at the DNA
level [48].
Materials and Methods
Ethics statement
The study was approved by the Ethical Committee at the
‘‘Eugenio Medea’’ Scientific Institute.
Human subjects
Blood samples were obtained from probands and their parents
after informed consent. All patients were referred for genetic
evaluation to different medical centers because of developmental
delay, delayed/absent language and dysmorphic features. Physical
examination and review of medical and family history records
were performed on each patient. The diagnosis of terminal 22q13
deletion syndrome had not been proposed in any of the patients
before identification of the deletion by cytogenetic or molecular
diagnostic analysis. Cytogenetic and molecular diagnosis had been
obtained by conventional karyotyping, subtelomere FISH, 22q13
MLPA analysis, or oligonucleotide-based aCGH (44k, 105k, 180k
or 244k Agilent platforms)(Table 1).
Array-CGH studies
A very high-resolution 22q13 custom array was designed
using the eArray software (http://earray.chem.agilent.com/);
probes were selected among those available in the Agilent
database (UCSC hg18, http://genome.ucsc.edu). A total of
24624 probes were selected within the distal 9.4 Mb region of
22q13 (chr22: 40269203–49565875), and 8660 probes within
the distal ,3.2 Mb of chromosome 12q (chr12: 129000012–
132289374); the latter set was used to identify the breakpoint
interval in cases with a derivative chromosome 22 associated
with a 12q genomic segment (P11, P15, P16), and for quality
control/normalization. The probes provided an average reso-
lution of 400 bp. Genomic DNA was isolated from blood
samples using the GenElute-Blood kit (Sigma). Gender-matched
genomic DNAs were obtained from individuals NA10851 (male)
and NA15510 (female) (Coriell). The quality of each DNA was
evaluated by conventional absorbance measurements (Nano-
Drop 1000, Thermo Scientific) and electrophoretic gel mobility
assays. Quality of experiments was assessed using Feature
Extraction QC Metric v10.1.1 (Agilent). The derivative log ratio
spread (DLR) value was calculated using the Agilent Genomics
Workbench software. Only experiments having a DLR spread
value ,0.30 were taken into consideration.
Cytogenetic and FISH analysis
Metaphase chromosomes and interphase nuclei were obtained
from all patients and their parents from PHA-stimulated blood
lymphocyte cultures. G-banding karyotypes at 400–550 bands
resolution were performed using standard high-resolution tech-
niques. FISH experiments with 22q13.3 subtelomeric cosmids
n66c4 (AC000050), n85a3 (AC000036), n94h12 (AC0020556)
and n1g3 (AC002055) [18] were performed to confirm the
aCGH results in cases where the 22q13.3 deletion disrupted the
SHANK3 gene (P31–32 P37–38, P42–43). FISH analysis with
BAC clones, labeled with biotin-dUTP (Vector laboratories,
Burligame, CA) using a nick translation kit (Roche), or probes for
all subtelomeric regions (TelVysion kit, VYSIS) were performed
on selected cases. The pan-telomeric peptide nucleic acid (PNA)
probe (PNA FISH kit/Cy3, Dako Denmark A/S) which
recognizes the consensus sequence (TTAGGG)n of human pan-
telomeres was hybridized according to the manufacturer’s
instructions.
Hybridizations were analyzed with an Olympus BX61 epi-
fluorescence microscope and images were captured with the Power
Gene FISH System (PSI, Newcastle-upon-Tyne, UK).
Parental origin determination
Genotyping of polymorphic sequence-tagged sites (STS) was
performed by amplification with primers labeled with fluorescent
probes followed by analysis on an ABI 310 Genetic Analyzer
(Applied Biosystems). In cases where STS analysis was not
informative, SNP genotyping was performed by PCR amplifica-
tion followed by sequencing. All amplifications were performed
with AmpliTaq Gold (Applied Biosystems) using standard
protocols.
Real-time PCR and MLPA analysis
Chromosome-specific target sequences for quantitative PCR
analysis were selected within non- repeated sequences using
Primer Express 2.0 software (Applied Biosystems) as described in
Bonaglia et al. [18]. The annotated genomic sequence of
chromosome 22 (March 2006 assembly, hg18) is available
through the UCSC Human Genome Browser (http://genome.
ucsc.edu/cgi.bin/Gateway). Multiplex Ligation-dependent Probe
Amplification analysis (MLPA) of the 22q13 region was
performed with the SALSA MLPA kit P188 22q13 (MRC-
Holland, Amsterdam).
Breakpoint cloning
Amplification of 22q13 deletions repaired by chromosome
healing was performed as in Bonaglia et al [18]. PCR
products were both directly sequenced and cloned with a
TOPO TA cloning kit (Invitrogen), followed by sequencing of
individual clones. Inverse PCR was performed on Sau3A-cut,
ligated (in 1 ml volume to facilitate self-ligation of individual
fragments) genomic DNA, using nested sets of primers. Long-
range PCRs were performed with JumpStart Red ACCUTaq
LA DNA polymerase (Sigma) and the following protocol:
30 sec at 96uC, 35 cycles of 15 sec at 94uC/20 sec at 58uC/
15 min at 68uC, 15 min final elongation time. Sequencing
reactions were performed with a Big Dye Terminator Cycle
Sequencing kit (Applied Biosystems) and run on an ABI Prism
3130xl Genetic Analyzer. Primer sequences are available in
Table S2.
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The accession number and URLs for data presented herein are
as follow: UCSC Human Genome Browser, http://genome.ucsc.
edu/cgi.bin/Gateway; Online Mendelian Inheritance in Man
(OMIM), http://www.ncbi.nlm.nih.gov/omim.
Supporting Information
Figure S1 Photographs of adult patients. Top, Subject P30 at
the age of 9 months (A), 13 months (B), 4 years (C); 8 years (D)
and 35 years (E). No significant craniofacial dysmorphisms can
be noticed, except for pointed chin (A,B,D), wide nasal bridge
(A,C), bulbous nose (C,D,E). Middle, Subject P10 at the age of
12 years (I) and at the age of 40 years; frontal (G,H) and lateral
(I) views. Note long face, large ears, full brow, prominent nasal
bridge, long and bulbous nose, short philtrum, asymmetric
mouth, thick lips. Bottom, Subject P33 in infancy (K),
adolescence (L) and frontal (M) and lateral (N) views at the
age of 41 years. Note the long eyelashes, full eyebrows, long and
prominent nose, low forehead, micrognathia, thick hair, large
ears, face asymmetry with hypo-mobility of the left side, small
mandible.
(TIF)
Figure S2 Sequences of all breakpoint junctions of terminal and
interstitial 22q13.3 deletions. The location of all sequences on the
hg18 Human Genome sequence is indicated. Repetitive sequences
are shown in lowercase letters. The identity of all repetitive
sequences is indicated in the Repeats column. Telomere repeat
sequences are shown in red. Genomic sequences with micro-
homology to the telomere repeat are underlined. TAR sequences
are shown in blue. Microhomologies at the junctions of interstitial
deletions are shown in bold.
(PDF)
Figure S3 Molecular characterisation of the 22q13.2 terminal
deletion in subject P12. A, Whole chromosome view and B, detail
of array-CGH analysis using an oligonucleotide-based custom
22q13 microarray. Arrowheads delimit two mosaic deleted
regions: the BP1–BP2 deletion region (from 44,606 kb to
45,600 kb) has an average log ratio of 20.8; the deleted region
between BP2 and the telomere (from 45,600 to 49,566 kb) has an
average log ratio of 21.0. C, Tel-ACP amplification and direct
sequencing of the amplified fragments revealed the breakpoint
junction at BP1. A telomere repeat is present at the breakpoint.
Repetitive sequences are shown in lowercase letters. Telomere
repeat sequences are shown in red. Genomic sequences with
microhomology to the telomere repeat are underlined.
(PDF)
Figure S4 Molecular characterisation of ring chromosome 22 in
subject P28. Whole chromosome 22 view (left) and details (right) of
a 180k Agilent array-CGH profile showing the 18 Mb duplication
at 22q11–12.3, the 4.2 Mb duplication at 22q12.3–13.2 and the
distal 240 kb deletion at 22q13.3.
(PDF)
Figure S5 Molecular characterisation of the ring 22-associated
deletion in subject P26. A, Whole chromosome view (left) and
detail (right) of array-CGH analysis using a 180k Agilent kit
microarray. B, Inverse-PCR amplification and direct sequencing
of the amplified fragments revealed the breakpoint junction.
Repetitive sequences are shown in lowercase letters. C, FISH
analysis using the PAN-Tel probe confirmed the deletion of the
22p and 22q telomeres of ring chromosome 22 (arrow).
(PDF)
Figure S6 Molecular characterisation of the 22q13.2 terminal
translocations in subjects P11, P15/P16. A, details of the of array-
CGH analysis using an oligonucleotide-based a 44k Agilent kit
microarray showing the breakpoint regions on chromosome 22q
(left) and 12q (right) in case P11. B, Long-range PCR
amplification and direct sequencing of the breakpoint junction.
Repetitive sequences are shown in lowercase letters. Micro-
homologies at the junction are shown in bold. C, details of the of
array-CGH analysis using an oligonucleotide-based 22q13
custom array (eArray, Agilent) showing the breakpoint regions
on chromosome 22q (left) and 12q (right) in cases P15/P16. D,
Long-range PCR amplification and direct sequencing of the
breakpoint junction.
(JPG)
Table S1 Clinical features of PMS patients compared to the
subjects in this study. (*) Prevalence according to Phelan, 2007
(Ref. [17]). (a) Accelerated growth was observed in 9 cases out
of 29, including the two patients (P26, P27) with ring 22 for
whom this information was available. In one patient (P25) with
ring 22, growth was slightly delayed, while short stature (,3
rd
centile) was observed in one subject (P38). (b) Brain imaging
studies, performed in 23 subjects, showed abnormal focal
signals in 5 patients (22%), diffuse hyperintensities of white
matter in three (13%), thin or short corpus callosum in 4
(17,4%), asymmetry or enlargement of lateral ventricles in 6
(26%) and arachnoid cysts in two patients (8.6%); the
remaining three cases had normal brain MRI. (c) According
to Havens et al. 2004 (Havens JM, Visootsak J, Phelan MC,
Graham JM Jr (2004) 22q13 deletion syndrome: an update and
review for the primary pediatrician. Clin Pediatr (Phila) 43:
43–53.) (d) Renal problems, including hydronephrosis (P5,
P36), right renal agenesis (P10), hypoplasia of right kidney
(P27) were ascertained in 10% of cases. (e) The following
behavioral disturbances were observed: hyperactivity, stereo-
types, poor concentration, poor social interactions, poor eye
contact, excessive screaming, and aggressiveness.
(PDF)
Table S2 Primers used for breakpoint cloning. Primer names,
sequences and amplification methods are indicated. Nested PCR
primers are indicated as F2, R2, F3, R3.
(PDF)
Text S1 Supplementary Clinical Information.
(PDF)
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